Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

89433

registered interest
date	29/08/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Prosthetics: Competition
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what assessment he has made of the competitiveness of the prosthesis manufacturing industry.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207338
answer	answer is ministerial correction date of answer 08/09/2014 answer text <p>The Government has not made a specific assessment of the competitiveness of the prosthesis manufacturing industry. However, prosthetics form a key part of the wider medical technology sector, and work is underway with the main medical technology trade associations (including the British Healthcare Trades Association (BHTA)), under the aegis of the Ministerial Medical Technology Strategy Group to identify and address the competitiveness challenges across the sector and its supply-chains.</p> answering member constituency West Suffolk answering member printed Matthew Hancock question first answered 08/09/2014 16:20:12 answering member 4070 label Biography information for Matt Hancock
tabling member	4037 label Biography information for Tom Blenkinsop

89567

registered interest
date	29/08/2014
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	Teachers: Disciplinary Proceedings
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Education, on how many occasions in the last 12 months decision-makers within her Department have issued sanctions to teachers after disciplinary hearings that have differed from the sanctions recommended by the Professional Conduct Panel of the National College for Teaching and Leadership; and in what respects those sanctions have differed from the recommended sanctions.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207201
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>In the period 1 September 2013 to 31 August 2014, decision makers issued sanctions to teachers after disciplinary hearings that differed from the sanctions recommended by the Professional Conduct Panel of the National College for Teaching and Leadership (NCTL) on seven occasions. Details are included within the table below.</p><table><tbody><tr><td><p>Number of Cases</p></td><td><p>Recommendation of panel</p></td><td><p>Final decision</p></td></tr><tr><td><p>3</p></td><td><p>No prohibition.</p></td><td><p>Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of two years.</p></td></tr><tr><td><p>3</p></td><td><p>Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of five years.</p></td><td><p>Prohibition for life with no opportunity to apply for the order to be set aside.</p></td></tr><tr><td><p>1</p></td><td><p>Prohibition for life with opportunity to apply for the order to be set aside after a minimum period of 10 years.</p></td><td><p>Prohibition for life with no opportunity to apply for the order to be set aside.</p></td></tr></tbody></table><p> </p> answering member constituency Yeovil answering member printed Mr David Laws question first answered 05/09/2014 09:28:39 answering member 1473 label Biography information for Mr David Laws
tabling member	4037 label Biography information for Tom Blenkinsop

89706

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps (a) his Department and (b) NHS England have taken to ensure that accessible information is produced about multiple sclerosis treatment options.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207186
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) clinical guideline <em>‘Multiple sclerosis: Management of multiple sclerosis in primary and secondary care’</em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient’s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.</p><p>We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.</p><p>The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207193 207203 207242 207243 question first answered 05/09/2014 11:00:42 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89711

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that regular reviews of treatment and care by multiple sclerosis (MS) specialists are available for all people with MS in England.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207243
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) clinical guideline <em>‘Multiple sclerosis: Management of multiple sclerosis in primary and secondary care’</em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient’s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.</p><p>We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.</p><p>The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207186 207193 207203 207242 question first answered 05/09/2014 11:00:42 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89716

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prosthetics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the practicality and safety of the recycling of prosthesis components issued by the NHS.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207347
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>No such assessment has been made of the practicality and safety of the recycling of prosthesis components issued by the National Health Service, or the cost to the NHS of repairs to prostheses in each of the last five years.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207348 question first answered 05/09/2014 09:43:48 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89717

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prosthetics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of repairs to prostheses in each of the last five years.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207348
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>No such assessment has been made of the practicality and safety of the recycling of prosthesis components issued by the National Health Service, or the cost to the NHS of repairs to prostheses in each of the last five years.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207347 question first answered 05/09/2014 09:43:48 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89720

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the provision of licensed treatments for multiple sclerosis in the NHS in England; and if he will take steps to increase the availability of such treatments.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207242
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) clinical guideline <em>‘Multiple sclerosis: Management of multiple sclerosis in primary and secondary care’</em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient’s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.</p><p>We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.</p><p>The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207186 207193 207203 207243 question first answered 05/09/2014 11:00:42 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89724

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he plans to take to increase the role of people with multiple sclerosis in decision-making processes relating to their treatment.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207193
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) clinical guideline <em>‘Multiple sclerosis: Management of multiple sclerosis in primary and secondary care’</em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient’s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.</p><p>We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.</p><p>The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207186 207203 207242 207243 question first answered 05/09/2014 11:00:42 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop

89726

registered interest
date	29/08/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that all people with relapsing remitting multiple sclerosis are invited to talk with a specialist about potential treatment options arising from new disease-modifying drugs.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	207203
answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) clinical guideline <em>‘Multiple sclerosis: Management of multiple sclerosis in primary and secondary care’</em>, published in 2003, set outs best practice in the care, treatment and support for people with this condition. The guidance emphasises that patients with multiple sclerosis (MS) should be involved in all decisions relating to their treatment and care and are supported to manage their condition. It also sets out that clinicians and other members of a patient’s healthcare team such as nurses and social workers, are responsible for discussing with patients the frequency and methods of reviewing their care needs.</p><p>We have made no recent assessment of the provision of licensed treatments for multiple sclerosis in the National Health Service in England. However, NICE has published technology appraisal guidance recommending a number of drugs for use in treating MS, subject to certain clinical criteria. There is a legal requirement on the NHS to provide funding for treatments and drugs recommended by NICE technology appraisal guidance within three months of NICE technology appraisal guidance being published. Clinicians should discuss with patients, including those with relapsing and remitting MS, the availability of any new treatments and the guideline makes clear that commissioners should ensure that all people with MS have ready access to a specialist neurological service which includes the provision of specific pharmacological treatments.</p><p>The guideline also stresses the importance of clinicians communicating clearly with patients which includes making leaflets and other information resources available. The provision of these resources is a matter for local NHS organisations.</p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 207186 207193 207242 207243 question first answered 05/09/2014 11:00:42 answering member 1439 label Biography information for Norman Lamb
tabling member	4037 label Biography information for Tom Blenkinsop